Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus
Abstract African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides . AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no o...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2014-09, Vol.32 (39), p.4932-4937 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4937 |
|---|---|
| container_issue | 39 |
| container_start_page | 4932 |
| container_title | Vaccine |
| container_volume | 32 |
| creator | Kanai, Yuta van Rijn, Piet A Maris-Veldhuis, Mieke Kaname, Yuki Athmaram, T.N Roy, Polly |
| description | Abstract African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides . AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and the immunogenicity of each was studied by immunization of guinea pigs with single VP2 as well as with cocktails of VP2 proteins. Homologous neutralizing antibodies measured by 50% plaque reduction assay showed varying degrees (from 37 to 1365) of titers for different VP2 proteins. A low cross-neutralizing antibody titer was found for genetically related AHSV serotypes. Immunization with VP2 cocktails containing equal amounts of each of the VP2 proteins also triggered neutralizing antibodies albeit to lower titers (4-117) to each of the serotypes in the cocktail. This study is a first step to develop a VP2 subunit vaccine for AHS and our results indicate that VP2 subunit vaccines are feasible individually or in a multi-serotype cocktail. |
| doi_str_mv | 10.1016/j.vaccine.2014.07.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4148702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X14009578</els_id><sourcerecordid>1846312301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c679t-b4ae532798509686c5363a337419f74817f83972c02ccd1eab06003d3a7d2e6a3</originalsourceid><addsrcrecordid>eNqNkt1rFDEQwBdRbK3-CcqCCL7cOfnOvrSU4kehoOAHvsVcdrbNdS85k92D--_NemerfalPgcxvJjOTX1U9JzAnQOSb5XxjnfMB5xQIn4OaAyMPqkOiFZtRQfTD6hCo5DNO4PtB9STnJQAIRprH1QEVwIUGcVj9OF-txhAvMXjnh20duzqhi6uFDzYM9bdPtF6nOKAPeYrZvq9DebTOWG63a_x9e9ol72yor2LKJeTddcCc641PY35aPepsn_HZ_jyqvr57--Xsw-zi4_vzs9OLmZOqGWYLblEwqhotoJFaOsEks4wpTppOcU1Up1mjqAPqXEvQLkACsJZZ1VKUlh1Vx7u663GxwtZhGJLtzTr5lU1bE603_0aCvzKXcWM44VoBLQVe7wuk-HPEPJiVzw773gaMYzZEc8kIZUDuR4UEQpRW_4MKzkVD2NTAyzvoMo4plKVNlFAgKKhCiR3lUsw5YXczIgEzmWGWZm-GmcwwoEwxo-S9-Hs_N1l_VCjAqz1gs7N9l2xwPt9yWklJJRTuZMdh-c2Nx2Sy8xgctr6YM5g2-ntbOb5TwfW--Gf7a9xivp3aZGrAfJ40niwmHKARSrNfuG7tdg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1555705207</pqid></control><display><type>article</type><title>Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Kanai, Yuta ; van Rijn, Piet A ; Maris-Veldhuis, Mieke ; Kaname, Yuki ; Athmaram, T.N ; Roy, Polly</creator><creatorcontrib>Kanai, Yuta ; van Rijn, Piet A ; Maris-Veldhuis, Mieke ; Kaname, Yuki ; Athmaram, T.N ; Roy, Polly</creatorcontrib><description>Abstract African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides . AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and the immunogenicity of each was studied by immunization of guinea pigs with single VP2 as well as with cocktails of VP2 proteins. Homologous neutralizing antibodies measured by 50% plaque reduction assay showed varying degrees (from 37 to 1365) of titers for different VP2 proteins. A low cross-neutralizing antibody titer was found for genetically related AHSV serotypes. Immunization with VP2 cocktails containing equal amounts of each of the VP2 proteins also triggered neutralizing antibodies albeit to lower titers (4-117) to each of the serotypes in the cocktail. This study is a first step to develop a VP2 subunit vaccine for AHS and our results indicate that VP2 subunit vaccines are feasible individually or in a multi-serotype cocktail.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.07.031</identifier><identifier>PMID: 25045805</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>African horse sickness ; African Horse Sickness - prevention & control ; African horse sickness virus ; African Horse Sickness Virus - classification ; Allergy and Immunology ; Animals ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Applied microbiology ; Baculoviridae ; Baculovirus ; Biological and medical sciences ; Capsid protein VP2 ; Capsid Proteins - immunology ; Confidence intervals ; Culicoides ; Female ; Fundamental and applied biological sciences. Psychology ; Genomes ; Guinea Pigs ; Horses ; immune response ; Immunization ; Immunogenicity ; Infections ; Microbiology ; Miscellaneous ; Molecular weight ; mortality ; Neutralization ; Neutralization Tests ; neutralizing antibodies ; Proteins ; Recombinant protein ; Recombinant Proteins - immunology ; Serogroup ; serotypes ; structural proteins ; Subunit vaccine ; subunit vaccines ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Subunit - immunology ; Viral Vaccines - immunology ; Virology ; viruses</subject><ispartof>Vaccine, 2014-09, Vol.32 (39), p.4932-4937</ispartof><rights>The Authors</rights><rights>2014 The Authors</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 3, 2014</rights><rights>2014 The Authors 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c679t-b4ae532798509686c5363a337419f74817f83972c02ccd1eab06003d3a7d2e6a3</citedby><cites>FETCH-LOGICAL-c679t-b4ae532798509686c5363a337419f74817f83972c02ccd1eab06003d3a7d2e6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1555705207?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,45974,64362,64364,64366,72216</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28766260$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25045805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanai, Yuta</creatorcontrib><creatorcontrib>van Rijn, Piet A</creatorcontrib><creatorcontrib>Maris-Veldhuis, Mieke</creatorcontrib><creatorcontrib>Kaname, Yuki</creatorcontrib><creatorcontrib>Athmaram, T.N</creatorcontrib><creatorcontrib>Roy, Polly</creatorcontrib><title>Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides . AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and the immunogenicity of each was studied by immunization of guinea pigs with single VP2 as well as with cocktails of VP2 proteins. Homologous neutralizing antibodies measured by 50% plaque reduction assay showed varying degrees (from 37 to 1365) of titers for different VP2 proteins. A low cross-neutralizing antibody titer was found for genetically related AHSV serotypes. Immunization with VP2 cocktails containing equal amounts of each of the VP2 proteins also triggered neutralizing antibodies albeit to lower titers (4-117) to each of the serotypes in the cocktail. This study is a first step to develop a VP2 subunit vaccine for AHS and our results indicate that VP2 subunit vaccines are feasible individually or in a multi-serotype cocktail.</description><subject>African horse sickness</subject><subject>African Horse Sickness - prevention & control</subject><subject>African horse sickness virus</subject><subject>African Horse Sickness Virus - classification</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Applied microbiology</subject><subject>Baculoviridae</subject><subject>Baculovirus</subject><subject>Biological and medical sciences</subject><subject>Capsid protein VP2</subject><subject>Capsid Proteins - immunology</subject><subject>Confidence intervals</subject><subject>Culicoides</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genomes</subject><subject>Guinea Pigs</subject><subject>Horses</subject><subject>immune response</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Infections</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Molecular weight</subject><subject>mortality</subject><subject>Neutralization</subject><subject>Neutralization Tests</subject><subject>neutralizing antibodies</subject><subject>Proteins</subject><subject>Recombinant protein</subject><subject>Recombinant Proteins - immunology</subject><subject>Serogroup</subject><subject>serotypes</subject><subject>structural proteins</subject><subject>Subunit vaccine</subject><subject>subunit vaccines</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Subunit - immunology</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><subject>viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkt1rFDEQwBdRbK3-CcqCCL7cOfnOvrSU4kehoOAHvsVcdrbNdS85k92D--_NemerfalPgcxvJjOTX1U9JzAnQOSb5XxjnfMB5xQIn4OaAyMPqkOiFZtRQfTD6hCo5DNO4PtB9STnJQAIRprH1QEVwIUGcVj9OF-txhAvMXjnh20duzqhi6uFDzYM9bdPtF6nOKAPeYrZvq9DebTOWG63a_x9e9ol72yor2LKJeTddcCc641PY35aPepsn_HZ_jyqvr57--Xsw-zi4_vzs9OLmZOqGWYLblEwqhotoJFaOsEks4wpTppOcU1Up1mjqAPqXEvQLkACsJZZ1VKUlh1Vx7u663GxwtZhGJLtzTr5lU1bE603_0aCvzKXcWM44VoBLQVe7wuk-HPEPJiVzw773gaMYzZEc8kIZUDuR4UEQpRW_4MKzkVD2NTAyzvoMo4plKVNlFAgKKhCiR3lUsw5YXczIgEzmWGWZm-GmcwwoEwxo-S9-Hs_N1l_VCjAqz1gs7N9l2xwPt9yWklJJRTuZMdh-c2Nx2Sy8xgctr6YM5g2-ntbOb5TwfW--Gf7a9xivp3aZGrAfJ40niwmHKARSrNfuG7tdg</recordid><startdate>20140903</startdate><enddate>20140903</enddate><creator>Kanai, Yuta</creator><creator>van Rijn, Piet A</creator><creator>Maris-Veldhuis, Mieke</creator><creator>Kaname, Yuki</creator><creator>Athmaram, T.N</creator><creator>Roy, Polly</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20140903</creationdate><title>Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus</title><author>Kanai, Yuta ; van Rijn, Piet A ; Maris-Veldhuis, Mieke ; Kaname, Yuki ; Athmaram, T.N ; Roy, Polly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c679t-b4ae532798509686c5363a337419f74817f83972c02ccd1eab06003d3a7d2e6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>African horse sickness</topic><topic>African Horse Sickness - prevention & control</topic><topic>African horse sickness virus</topic><topic>African Horse Sickness Virus - classification</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Applied microbiology</topic><topic>Baculoviridae</topic><topic>Baculovirus</topic><topic>Biological and medical sciences</topic><topic>Capsid protein VP2</topic><topic>Capsid Proteins - immunology</topic><topic>Confidence intervals</topic><topic>Culicoides</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genomes</topic><topic>Guinea Pigs</topic><topic>Horses</topic><topic>immune response</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Infections</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Molecular weight</topic><topic>mortality</topic><topic>Neutralization</topic><topic>Neutralization Tests</topic><topic>neutralizing antibodies</topic><topic>Proteins</topic><topic>Recombinant protein</topic><topic>Recombinant Proteins - immunology</topic><topic>Serogroup</topic><topic>serotypes</topic><topic>structural proteins</topic><topic>Subunit vaccine</topic><topic>subunit vaccines</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Subunit - immunology</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><topic>viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanai, Yuta</creatorcontrib><creatorcontrib>van Rijn, Piet A</creatorcontrib><creatorcontrib>Maris-Veldhuis, Mieke</creatorcontrib><creatorcontrib>Kaname, Yuki</creatorcontrib><creatorcontrib>Athmaram, T.N</creatorcontrib><creatorcontrib>Roy, Polly</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanai, Yuta</au><au>van Rijn, Piet A</au><au>Maris-Veldhuis, Mieke</au><au>Kaname, Yuki</au><au>Athmaram, T.N</au><au>Roy, Polly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2014-09-03</date><risdate>2014</risdate><volume>32</volume><issue>39</issue><spage>4932</spage><epage>4937</epage><pages>4932-4937</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides . AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and the immunogenicity of each was studied by immunization of guinea pigs with single VP2 as well as with cocktails of VP2 proteins. Homologous neutralizing antibodies measured by 50% plaque reduction assay showed varying degrees (from 37 to 1365) of titers for different VP2 proteins. A low cross-neutralizing antibody titer was found for genetically related AHSV serotypes. Immunization with VP2 cocktails containing equal amounts of each of the VP2 proteins also triggered neutralizing antibodies albeit to lower titers (4-117) to each of the serotypes in the cocktail. This study is a first step to develop a VP2 subunit vaccine for AHS and our results indicate that VP2 subunit vaccines are feasible individually or in a multi-serotype cocktail.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>25045805</pmid><doi>10.1016/j.vaccine.2014.07.031</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2014-09, Vol.32 (39), p.4932-4937 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4148702 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | African horse sickness African Horse Sickness - prevention & control African horse sickness virus African Horse Sickness Virus - classification Allergy and Immunology Animals Antibodies, Neutralizing - blood Antibodies, Viral - blood Applied microbiology Baculoviridae Baculovirus Biological and medical sciences Capsid protein VP2 Capsid Proteins - immunology Confidence intervals Culicoides Female Fundamental and applied biological sciences. Psychology Genomes Guinea Pigs Horses immune response Immunization Immunogenicity Infections Microbiology Miscellaneous Molecular weight mortality Neutralization Neutralization Tests neutralizing antibodies Proteins Recombinant protein Recombinant Proteins - immunology Serogroup serotypes structural proteins Subunit vaccine subunit vaccines Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Subunit - immunology Viral Vaccines - immunology Virology viruses |
| title | Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T05%3A02%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20recombinant%20VP2%20proteins%20of%20all%20nine%20serotypes%20of%20African%20horse%20sickness%20virus&rft.jtitle=Vaccine&rft.au=Kanai,%20Yuta&rft.date=2014-09-03&rft.volume=32&rft.issue=39&rft.spage=4932&rft.epage=4937&rft.pages=4932-4937&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2014.07.031&rft_dat=%3Cproquest_pubme%3E1846312301%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1555705207&rft_id=info:pmid/25045805&rft_els_id=S0264410X14009578&rfr_iscdi=true |